Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of SYL1001 ophthalmic solution in patients with ocular pain associated with dry eye
2014-004857-15Phase 2Completed
- Sponsor
- Sylentis
- Start
- Mar 2015
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of tivanisiran in dry eye syndrome (DED), sponsored by Sylentis. Primary endpoint: Analgesic effect of SYL1001. Started Mar 2015; status: completed.
02
Drugs
tivanisiran
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on 2014-004857-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004857-15.